From Mr Paavo Järvensivu.

Sir, David Shaywitz and Nassim Taleb (“Drug research needs serendipity”, July 30) see a match between agile innovators that provide cutting-edge research and pharma companies that can bring this research into the market by orchestrating the entire process. While this kind of arrangement may seem promising at first sight, there is a major caveat.